Oxurion 
Welcome,         Profile    Billing    Logout  
 4 Products   36 Diseases  4 Products   1 Trial   271 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jetrea (ocriplasmin) / Oxurion
2005-003224-19: Clinical Trial of Microplasmin in Patients with Long-Term Venous Access Catheter Thrombosis

Not yet recruiting
2
56
Europe
microplasmin, µPL, Intravenous infusion
UZ Leuven - Bloedings- en Vaatziekten
Thrombotic occlusion of central venous access devices
 
 
THR-149 / Oxurion
2019-001506-17: A study to evaluate THR-149 treatment for diabetic macular oedema

Not yet recruiting
2
126
Europe, RoW
THR-149, Aflibercept, THR-149, Solution for injection, Eylea 40 mg/ml solution for injection
Oxurion NV, OXURION NV, Oxurion NV
Diabetic Macular Oedema (DME), Diabetic macular oedema is a swelling in the light-sensitive tissue in the back of the eye (called the retina) in people with diabetes, caused by leaking of blood vessels., Diseases [C] - Eye Diseases [C11]
 
 
KALAHARI, NCT04527107 / 2019-001506-17: A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Completed
2
135
Europe, US, RoW
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Oxurion, Oxurion NV
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
09/23
11/23
23A11 / Oxurion
No trials found
IO-1 / Oxurion
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jetrea (ocriplasmin) / Oxurion
2005-003224-19: Clinical Trial of Microplasmin in Patients with Long-Term Venous Access Catheter Thrombosis

Not yet recruiting
2
56
Europe
microplasmin, µPL, Intravenous infusion
UZ Leuven - Bloedings- en Vaatziekten
Thrombotic occlusion of central venous access devices
 
 
THR-149 / Oxurion
2019-001506-17: A study to evaluate THR-149 treatment for diabetic macular oedema

Not yet recruiting
2
126
Europe, RoW
THR-149, Aflibercept, THR-149, Solution for injection, Eylea 40 mg/ml solution for injection
Oxurion NV, OXURION NV, Oxurion NV
Diabetic Macular Oedema (DME), Diabetic macular oedema is a swelling in the light-sensitive tissue in the back of the eye (called the retina) in people with diabetes, caused by leaking of blood vessels., Diseases [C] - Eye Diseases [C11]
 
 
KALAHARI, NCT04527107 / 2019-001506-17: A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Completed
2
135
Europe, US, RoW
THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg
Oxurion, Oxurion NV
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
09/23
11/23
23A11 / Oxurion
No trials found
IO-1 / Oxurion
No trials found

Download Options